Sugary Drinks Linked To Shock Cancer Jump

People who drink at least one soda or sugary drink every day face more than double the risk of stomach cancer compared to those who rarely touch the stuff, according to a new study from Mass General Brigham Cancer Institute.

Story Snapshot

Mass General Brigham researchers found a 2.45-fold higher gastric cancer risk in daily sugar-sweetened drink consumers versus rare drinkers.
The study tracked more than 100,000 people over several decades, one of the largest datasets used to examine this question.
Artificially sweetened beverages showed no increased cancer risk in the same research.
Earlier studies, including a large Japanese cohort, found no link at all between sugary drinks and stomach cancer risk.

What The New Study Actually Found

Researchers at Mass General Brigham Cancer Institute studied people who drank sugary beverages daily. They compared them to people who drank these beverages less than once a month. The daily drinkers had more than double the risk of developing gastric cancer. The study defined sugary drinks broadly. Sodas, fruit punch, lemonade, and sports drinks all counted toward the daily total.

The findings appeared in the journal Gastro Hep Advances. Researchers adjusted for other risk factors like smoking, alcohol use, and body weight. Even after those adjustments, the sugary drink connection held strong. Diet soda drinkers did not show the same pattern. That detail matters because it points away from the sweet taste itself and toward the sugar content specifically.

Why This Number Stands Out From Past Research

Stomach cancer research has a messy history. A major Japanese study following more than 2,000 cancer cases for nearly 17 years found no connection between sugary drinks and stomach cancer risk at all. A 2021 review of dozens of observational studies reached a similar conclusion. Most gastric cancer analyses in that review showed no significant association with sugary or artificially sweetened beverages.

A 2018 review of the broader sugar-and-cancer literature found something in between. Most studies pointed to no connection. But roughly half the studies specifically looking at sugary beverages found higher cancer risk, ranging from 23 percent to 200 percent. That range is wide enough to explain why one bombshell study can grab headlines while the overall scientific consensus stays cautious.

The Pattern Behind Every Sugar-Cancer Headline

Nutrition science works in waves. A single cohort study reports a dramatic number. Then years of meta-analyses and pooled reviews chip away at that number until it shrinks toward zero, or the signal moves to a different cancer type entirely. That is exactly what happened with pancreatic and colorectal cancers, where a large 2026 global review found a probable causal link to sugary drinks, while gastric cancer results stayed inconsistent across studies.

None of this means the Mass General Brigham findings are wrong. Peer-reviewed publication and a sample size over 100,000 carry real weight. But readers should know this single study sits inside a field where gastric cancer results have swung both directions for over a decade. Common sense says an association this strong deserves attention, not panic, and definitely deserves replication before anyone rewrites dietary guidelines.

What Health Officials Already Recommend

The Centers for Disease Control and Prevention reports that 63 percent of American adults drink sugar-sweetened beverages at least once daily. That habit already carries well-documented risks tied to obesity, diabetes, and heart disease, regardless of where the cancer research eventually lands. The World Cancer Research Fund has long urged people to limit sugary drinks based on strong evidence tied to weight gain alone. That guidance does not depend on resolving the gastric cancer debate.

Families weighing daily habits do not need to wait for scientific consensus to cut back on soda and sports drinks. The weight-gain and diabetes risks are already settled science. The cancer question remains genuinely open, with credible researchers landing on different sides depending on the population studied and the cancer subtype measured. Treat this new study as a serious warning worth watching, not a final verdict.